Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer.
Sign Up to like & getrecommendations! Published in 2020 at "JAMA network open"
DOI: 10.1001/jamanetworkopen.2020.11818
Abstract: Importance Robust predictors for response to anti-programmed death 1 and its ligand (PD-1/PD-L1) immunotherapy in non-small cell lung cancer (NSCLC) are not fully characterized. Objective To evaluate whether PD-L1 (CD274) copy number gains (CNGs), comprising… read more here.
Keywords: nivolumab monotherapy; response; response nivolumab; programmed death ... See more keywords
Programmed Death Ligand-1-Overexpressing Donor Exosomes Mediate Donor-Specific Immunosuppression by Delivering Co-inhibitory Signals to Donor-Specific T Cells.
Sign Up to like & getrecommendations! Published in 2023 at "Advanced healthcare materials"
DOI: 10.1002/adhm.202300670
Abstract: Programmed death ligand-1 (PD-L1) and donor antigens are critical for donor immature dendritic cells (DCs) targeting donor-specific T cells to induce transplant tolerance. This study aimed to clarify whether DC-derived exosomes (DEX) with donor antigens… read more here.
Keywords: inhibitory signals; specific cells; donor specific; donor ... See more keywords
Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort study
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5661
Abstract: Lenvatinib plus anti‐programmed death‐1 (anti‐PD‐1) antibody combinations have shown potent anti‐tumor effect in phase I/II trials in advanced or unresectable hepatocellular carcinoma (HCC), but real‐world data are limited. read more here.
Keywords: hepatocellular carcinoma; plus anti; programmed death; anti programmed ... See more keywords
Role of tumor microenvironment in cancer progression and therapeutic strategy.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.5698
Abstract: Cancer is now considered a tumor microenvironment (TME) disease, although it was originally thought to be a cell and gene expression disorder. Over the past 20 years, significant advances have been made in understanding the complexity… read more here.
Keywords: progression; tumor microenvironment; programmed death; tumor ... See more keywords
Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade
Sign Up to like & getrecommendations! Published in 2024 at "Cancer"
DOI: 10.1002/cncr.35179
Abstract: Programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) blockade has changed the landscape of treatment for metastatic urothelial cancer, but single‐agent cytotoxic T‐lymphocyte–associated protein 4 (CTLA‐4) blockade in metastatic urothelial cancer has been underexplored. A… read more here.
Keywords: urothelial cancer; metastatic urothelial; programmed death; death programmed ... See more keywords
Programmed death ligand 1 testing in non–small cell lung carcinoma cytology cell block and aspirate smear preparations
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Cytopathology"
DOI: 10.1002/cncy.21987
Abstract: Immune checkpoint inhibitors targeting the programmed cell death 1 (PD‐1) receptor and its ligand, programmed death ligand 1 (PD‐L1), have emerged as a therapeutic approach for patients with non–small cell lung carcinoma (NSCLC). PD‐L1 expression,… read more here.
Keywords: programmed death; cell; cytology; death ligand ... See more keywords
Clinical performance of endobronchial ultrasound‐guided transbronchial needle aspiration for assessing programmed death ligand‐1 expression in nonsmall cell lung cancer
Sign Up to like & getrecommendations! Published in 2018 at "Diagnostic Cytopathology"
DOI: 10.1002/dc.23900
Abstract: Pembrolizumab was recently approved as a first line agent for metastatic NSCLC in patients with high programmed death‐ligand 1 (PD‐L1) expression. read more here.
Keywords: ligand expression; programmed death; death ligand;
Expression of programmed death‐1 in sentinel lymph nodes of breast cancer
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.24937
Abstract: To explore whether lymphocytes in sentinel lymph nodes (SLNs) are highly exposed to tumor neoantigens and thus express high level of programmed death 1 (PD‐1), we examined PD‐1 expression in SLNs and non‐sentinel regional lymph… read more here.
Keywords: lymph nodes; breast cancer; programmed death; expression ... See more keywords
Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-020-02654-0
Abstract: Dendritic cell (DC)-based vaccines are recognized as a promising immunotherapeutic strategy against cancer; however, the efficacy of immunotherapy with DCs is controlled via immune checkpoints, such as programmed death-ligand 1 (PD-L1). PD-L1 expressed on DC… read more here.
Keywords: programmed death; dendritic cell; death ligand; myeloma ... See more keywords
Comparison of programmed death ligand-1 expression in preoperative transbronchial lung biopsy and resected specimens in non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-025-06189-8
Abstract: Programmed death-ligand 1 expression is heterogeneous in non-small cell lung cancer, and small specimens may not accurately represent the entire tumor. The current study investigated the discordance in programmed death-ligand 1 expression between preoperative biopsy… read more here.
Keywords: death ligand; biopsy; programmed death; lung ... See more keywords
Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-021-01993-x
Abstract: Programmed death-ligand 1 (PD-L1) positivity is associated with poor prognosis in renal cell carcinoma (RCC). Because the prognostic impact and effect of confounding factors are less known, we investigated the prognostic significance of PD-L1 expression… read more here.
Keywords: status; renal cell; cell carcinoma; japanese patients ... See more keywords